Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $4.03, but opened at $4.58. Evotec shares last traded at $4.72, with a volume of 288,664 shares traded.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on EVO. Royal Bank of Canada restated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $5.93.
Check Out Our Latest Research Report on EVO
Evotec Price Performance
The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The firm has a 50 day moving average price of $3.75 and a 200-day moving average price of $4.18.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of Evotec in the 4th quarter valued at $27,000. CSS LLC IL purchased a new position in Evotec in the fourth quarter valued at $50,000. Bank of America Corp DE raised its stake in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new stake in Evotec in the fourth quarter valued at $166,000. Finally, ABC Arbitrage SA purchased a new stake in Evotec during the 1st quarter worth about $260,000. Hedge funds and other institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
